Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Alignment Healthcare, Inc. (ALHC) reported that Chief Executive Officer and director John E. Kao disclosed two sales of common stock totaling 557,870 shares.
On September 11, 2026, Kao sold 385,270 shares at a weighted-average price of $12.68 per share, in multiple trades between $12.394 and $13.17, to cover tax withholding obligations arising from the vesting of restricted stock units; the filing states this was not a discretionary trade. After this sale, he held 1,223,473 shares directly.
On September 10, 2026, a trust associated with Kao, the JEK Trust dated February 8, 2021, sold 172,600 shares at a weighted-average price of $12.96 per share, in trades between $12.71 and $13.21, under a Rule 10b5-1 trading plan adopted on May 27, 2026. These shares are reported as held indirectly, with 618,166 shares remaining in the trust after the transaction.
Alignment Healthcare, Inc. (ALHC) is the issuer of common stock covered by this notice, which states that JEK TRUST U/A DTD 02/08/2021 plans to sell 500,000 shares of ALHC common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The shares were originally issued pre-IPO in exchange for partnership units.
Alignment Healthcare, Inc. (ALHC) received a Rule 144 notice from President Dawn C. Maroney covering a proposed sale of 130,000 shares of common stock through E-Trade, with an indicated aggregate market value of $1,697,800 and 207,435,149 shares of common stock outstanding. The shares to be sold were acquired through the vesting of restricted stock units granted on September 12, 2022 under the company’s 2021 Equity Incentive Plan, and the filing notes the transaction is a sale-to-cover for tax withholding rather than a discretionary trade.
Alignment Healthcare, Inc. (ALHC) disclosed a planned sale of up to 405,000 shares of common stock under Rule 144 for the account of Chief Executive Officer and Director John Kao. The shares relate to equity awards, including 819,513 shares acquired through vesting of restricted stock units on September 12, 2022 under the company’s 2021 Equity Incentive Plan.
The notice states that the transaction is a sale-to-cover for tax withholding and does not represent a discretionary trade by John Kao; the actual number of shares sold will depend on applicable tax withholding rates and the stock price at the time of sale. In the prior three months, entities under a 10b5-1 Sales Plan associated with Kao reported three sales of 298,000 shares each.
Alignment Healthcare, Inc. (ALHC) reported an insider transaction by President Dawn Christine Maroney. On 2026-08-14, she sold 5,000 shares of common stock at $14.00 per share in an open-market or private transaction. After this sale, she directly held 917,313 shares of Alignment Healthcare common stock. The transaction was carried out under a Rule 10b5-1 trading plan adopted on 2026-03-13.
A shareholder associated with ALHC filed a Rule 144 notice indicating an intention to sell 5,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate value of $67,300. These shares relate to RSU/PSU awards dated September 25, 2020.
Within the past three months, the same filer executed 10b5-1 plan sales of common stock totaling 237,068 shares, including 177,068 shares for $3,687,990.22 on July 15, 2026, and two 30,000‑share sales for $586,424.50 and $482,567.00.
Invesco Ltd., as a parent holding company to its investment advisers, reports beneficial ownership of 10,365,640 shares of Alignment Healthcare Inc. common stock, representing 5.0% of the outstanding class. These shares are held of record by clients of Invesco’s advisory entities.
Invesco has sole voting power over 9,985,762 shares and sole dispositive power over all 10,365,640 shares, with no shared voting or dispositive authority. No single client has more than a 5% economic interest in the securities; the relevant clients are entitled to dividends and sale proceeds. Subsidiaries involved include Invesco Advisers, Inc., Invesco Asset Management Limited, and Invesco Capital Management LLC.
Alignment Healthcare, Inc. insider John E. Kao, Chief Executive Officer and director, reported selling 298,000 shares of common stock on 2026-08-10 at a weighted-average price of $13.8818 per share, in multiple trades between $13.62 and $14.30. The sold shares are held indirectly through the JEK Trust, where Mr. Kao serves as trustee, leaving 790,766 common shares held indirectly after the sale. A separate entry shows 1,608,743 common shares held directly as of the same date. The filing states that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on 11/21/2025.
Vanguard Portfolio Management LLC reports beneficial ownership of Alignment Healthcare Inc. common stock. It beneficially owns 11,874,585 shares, representing 5.74% of the outstanding common stock. Vanguard has sole voting power over 202,326 shares and sole dispositive power over 11,874,585 shares, with no shared voting or dispositive power.
The holdings reflect securities beneficially owned, or deemed beneficially owned, by Vanguard Portfolio Management LLC and specified Vanguard affiliates, including registered funds and other managed accounts. Vanguard entities have rights to dividends and sale proceeds on these securities, but no single other person’s interest exceeds 5% of the class.